Recombinant DNA technology market seen reaching $1.4 trillion by 2030

The global recombinant DNA technology market is projected to grow from $998.83 billion in 2026 to $1.41 trillion by 2030, driven by gene therapy, personalized medicine and CRISPR adoption. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Recombinant DNA technology is becoming a bigger commercial engine across medicine, agriculture and industrial biotech. - The market’s projected growth signals rising demand for gene therapies, recombinant vaccines and scalable biomanufacturing. - Crop biotechnology remains a major growth driver as genetically modified seeds gain wider use.

What happened: - The Business Research Company published its "Recombinant DNA Technology Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035." - The report says the market will rise from $913.42 billion in 2025 to $998.83 billion in 2026. - The report projects the market will reach $1,414.92 billion by 2030. - The forecast implies a 9.1% compound annual growth rate through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing regional market.

The details: - Recombinant DNA technology combines DNA from different organisms and inserts the new material into host cells to create new genetic combinations. - The technology is used in science, medicine, agriculture and industry. - The report ties recent growth to molecular biology research, chronic disease prevalence, biologics production, academic and government funding, and early commercialization of recombinant therapies. - The company also cites increased investment in gene therapy, broader CRISPR use, sustainable bioproduction and stronger academia-industry collaboration as future drivers. - The report highlights growing gene editing adoption, recombinant vaccine development, advanced expression systems, cell and gene therapy pipelines and scalable biomanufacturing. - In December 2023, the U.S. Department of Agriculture reported that Canada cultivated 11.7 million hectares of genetically engineered crops, mainly canola, soybeans and corn. - That acreage was up 4% from 2022, largely because of expanded canola cultivation. - The report includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies and future trends, and updated graphics and tables. - Download a free sample of the report - View the full report

Between the lines: - The forecast suggests recombinant DNA is shifting from a research platform into a broader commercial infrastructure for therapeutics and agricultural productivity. - Regional leadership remains concentrated in North America, but faster growth in Asia-Pacific points to expanding biotech capacity and demand outside the U.S. and Europe. - The emphasis on scalable biomanufacturing and expression systems signals a market focused on moving from innovation to production efficiency.

What's next: - The market is expected to keep expanding through 2030 as gene therapy and personalized medicine move further into clinical and commercial use. - Broader CRISPR adoption and cell and gene therapy pipeline growth are likely to shape product development and investment priorities. - Genetic engineering in agriculture will remain a supporting demand driver as crop biotech adoption increases.